1332531-57-3 Usage
General Description
The chemical compound "(2-{5-[(2-Fluorophenoxy)methyl]-1,2,4-oxadiazol-3-yl}ethyl)methylamine hydrochloride" is a derivative of methylamine that contains a 1,2,4-oxadiazole ring and a fluorophenoxy group. It is a hydrochloride salt, meaning the amine group in the compound is protonated by hydrochloric acid. (2-{5-[(2-Fluorophenoxy)methyl]-1,2,4-oxadiazol-3-yl}ethyl)methylamine hydrochloride has potential biological activity and may be used in medicinal chemistry research for the development of new drugs. The presence of the oxadiazole ring and the fluorophenoxy group could give this compound interesting pharmacological properties and it may be investigated for its potential as a therapeutic agent. Additionally, the inclusion of the hydrochloride salt form allows for increased solubility and potential for use in pharmaceutical formulations.
Check Digit Verification of cas no
The CAS Registry Mumber 1332531-57-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,3,2,5,3 and 1 respectively; the second part has 2 digits, 5 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1332531-57:
(9*1)+(8*3)+(7*3)+(6*2)+(5*5)+(4*3)+(3*1)+(2*5)+(1*7)=123
123 % 10 = 3
So 1332531-57-3 is a valid CAS Registry Number.
1332531-57-3Relevant articles and documents
Privileged 1,2,4-oxadiazoles in anticancer drug design: Novel 5-aryloxymethyl-1,2,4-oxadiazole leads for prostate cancer therapy
Lukin, Alexey,Karapetian, Ruben,Ivanenkov, Yan,Krasavin, Mikhail
, p. 198 - 204 (2016/03/15)
Based on the structure of the previously identified leads, new series of compounds containing 1,2,4-oxadiazole core was designed. A small, diverse library of 51 compounds including both 2-(acylamino)ethyl and 2-ureidoethyl side chains was synthesized using parallel chemistry and tested for antiproliferative activity against prostate cancer DU-145 cell line. Four hit compounds - all belonging to 2-ureidoethyl series - were identified and three compounds were confirmed as 10-20 μM inhibitors. The similarity in compounds' periphery and the data obtained previously suggest a similar mode of action for these compounds which was postulated as tubulin inhibition and was confirmed by in silico docking. These data provide further evidence for the privileged character of 1,2,4-oxadiazoles in antiproliferative compound design.
